Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with interferon alfa-2a and vinblastine as first-line treatment for metastatic renal cell carcinoma
2005-006161-13Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, interferon alfa-2a and vinblastine in renal cell carcinoma (RCC), sponsored by Roche. Started Oct 2006; status: completed.
02
Drugs
bevacizumabinterferon alfa-2avinblastine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2005-006161-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006161-13.